Drugs / Celecoxib
last change 3 days ago re-read 2 minutes ago

Celecoxib

Other / unclassified targets ABCB1, CYP2D6, GATA6, PTGS2 via inhibition

Developed for
colorectal cancer · lung cancer · breast cancer · osteoarthritis, knee · osteoarthritis · head and neck cancer · female breast carcinoma · prostate cancer
+181 more · esophageal cancer · non-small cell lung carcinoma · malignant pancreatic neoplasm · sarcoma · cancer of unknown primary site · colon carcinoma · hypertensive disorder · neuropathy, painful · precancerous condition · rheumatoid arthritis · cancer · chronic pain syndrome · COVID-19 · major depressive disorder · triple-negative breast carcinoma · amyotrophic lateral sclerosis · childhood malignant neoplasm · metastatic malignant neoplasm · neuroblastoma · osteoarthritis, hip · pancreatic adenocarcinoma · rotator cuff syndrome · Alzheimer disease · ankylosing spondylitis · arthritic joint disease · atypical teratoid rhabdoid tumor · bipolar depression · central nervous system neoplasm · classic familial adenomatous polyposis · classic or attenuated familial adenomatous polyposis · colorectal carcinoma · colorectal neoplasm · glioblastoma · hepatocellular carcinoma · hypopharyngeal carcinoma · intestinal polyp · intracerebral hemorrhage · juvenile idiopathic arthritis · laryngeal carcinoma · liver cancer · long COVID-19 · lymphoma · macular degeneration · migraine disorder · nasopharyngeal carcinoma · nicotine dependence · obesity disorder · obsessive-compulsive disorder · oral cavity cancer · oral cavity carcinoma · oropharyngeal carcinoma · ovarian cancer · ovarian carcinoma · peptic ulcer disease · plasma cell myeloma · rectal carcinoma · schizophrenia · skin carcinoma · spondyloarthropathy · tonsillitis · type 2 diabetes mellitus · urinary bladder cancer · uterine cervix carcinoma in situ · amnestic disorder · aspirin-induced respiratory disease · autonomic nervous system disorder · benign prostatic hyperplasia · bile duct cancer · bipolar disorder · bladder transitional cell carcinoma · brain stem glioma · breast carcinoma · breast carcinoma in situ · central nervous system cancer · central serous chorioretinopathy · cervical cancer · cervical carcinoma · cervical intraepithelial neoplasia grade 2/3 · cervical squamous intraepithelial neoplasia · childhood medulloblastoma · chronic prostatitis · chronic rhinosinusitis · colonic neoplasm · coronary artery disorder · coronary restenosis · depressive disorder · diabetic kidney disease · diarrheal disease · diffuse large B-cell lymphoma · embryonal tumor with multilayered rosettes · endocrine exophthalmos · endometrial cancer · ependymoblastoma · esophageal squamous cell carcinoma · fallopian tube cancer · gastric carcinoma · gastroesophageal cancer · glioma · gout · hereditary nonpolyposis colon cancer · hyalitis · hypoproteinemia, hypercatabolic · ileus · influenza · intrahepatic cholangiocarcinoma · larynx cancer · larynx squamous papilloma · leukemia · ligament disorder · lumbar spinal stenosis · lung carcinoma · lymphangioleiomyomatosis · macular retinal edema · malignant epithelial tumor of ovary · malignant peritoneal mesothelioma · medulloblastoma · medulloblastoma non-WNT/non-SHH group 3 · medulloblastoma non-WNT/non-SHH group 4 · medulloepithelioma · melanoma · mesothelioma · metastatic carcinoma · metastatic neoplasm · mouth disorder · musculoskeletal system disorder · myositis ossificans · nasal cavity and paranasal sinus carcinoma · neoplasm · neurofibromatosis type 1 · non-invasive bladder urothelial carcinoma · occlusion of tributary of retinal vein · oral cavity squamous cell carcinoma · orthostatic hypotension · osteochondritis dissecans · ovarian neoplasm · pancreatic neoplasm · paranasal sinus neoplasm · peritoneal carcinomatosis · peritoneum cancer · Peutz-Jeghers syndrome · pharyngitis · pharynx cancer · pineoblastoma · pleural mesothelioma · postpartum depression · preeclampsia · preretinal fibrosis · primary peritoneal carcinoma · pulpitis · rectal cancer · renal cell carcinoma · small cell lung carcinoma · spinal muscular atrophy · squamous cell carcinoma · squamous cell carcinoma of buccal mucosa · subacute thyroiditis · temporomandibular joint disorder · thymoma · tongue cancer · trigeminal neuralgia · tuberculosis · tumor of duodenum · ureterolithiasis · urinary tract infection · uterine cancer · acute respiratory distress syndrome · brain cancer · colorectal adenoma · coronary atherosclerosis · Crohn disease · epilepsy · gastric ulcer · germ cell tumor · hand-foot syndrome · hormone-resistant prostate carcinoma · osteoarthritis, hand · Parkinson disease · prostate adenocarcinoma · recurrent respiratory papillomatosis · rheumatic disorder · uterine inflammatory disease
Investigated by
National Cancer Institute (NCI) · Viatris Inc. · Pfizer · M.D. Anderson Cancer Center · Sun Yat-sen University · Dana-Farber Cancer Institute
+334 more · Roswell Park Cancer Institute · Emory University · University of Alabama at Birmingham · Alliance for Clinical Trials in Oncology · Barbara Ann Karmanos Cancer Institute · City of Hope Medical Center · Pharmacia · United States Department of Defense · Vanderbilt-Ingram Cancer Center · HaEmek Medical Center, Israel · Henry Ford Health System · Jonsson Comprehensive Cancer Center · National Institute of Mental Health (NIMH) · Northwestern University · Seoul National University Hospital · University of California, Los Angeles · Brigham and Women's Hospital · Buddhist Tzu Chi General Hospital · Cairo University · Case Comprehensive Cancer Center · Dr. Reddy's Laboratories Limited · Hartford Hospital · Leidos Life Sciences · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Memorial Sloan Kettering Cancer Center · National Institute of Dental and Craniofacial Research (NIDCR) · Oregon Health and Science University · Seoul National University Bundang Hospital · Stanley Medical Research Institute · University of California, San Francisco · University of Michigan · University of Michigan Rogel Cancer Center · University of Pennsylvania · University of Southern California · University of Utah · Vanderbilt University · AIM ImmunoTech Inc. · Anticancer Fund, Belgium · Arthritis Innovation Corporation · AstraZeneca · Boehringer Ingelheim · Bristol-Myers Squibb · Centre Hospitalier Universitaire Vaudois · Chang Gung Memorial Hospital · Changhua Christian Hospital · Chi Mei Medical Hospital · Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Department of Veterans Affairs, New Jersey · Eli Lilly and Company · European Organisation for Research and Treatment of Cancer - EORTC · Fox Chase Cancer Center · GERCOR - Multidisciplinary Oncology Cooperative Group · Gynecologic Oncology Group · Indiana University · Johns Hopkins University · Laboratorios Silanes S.A. de C.V. · Mackay Memorial Hospital · Massachusetts General Hospital · Mayo Clinic · Merck Sharp & Dohme LLC · Myopharm Limited · National Center for Advancing Translational Sciences (NCATS) · National Cheng-Kung University Hospital · National Eye Institute (NEI) · National Health Research Institutes, Taiwan · National Heart, Lung, and Blood Institute (NHLBI) · National Taiwan University Hospital · National University Hospital, Singapore · NeuroSense Therapeutics Ltd. · Ohio State University Comprehensive Cancer Center · Organon and Co · POZEN · Patient-Centered Outcomes Research Institute · Princess Margaret Hospital, Canada · all 340 on the full record

Regulatory milestones approvals, filings & regulatory actions · 9 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (6) US (FDA) CELEBREX 2001-10-18 – 2018-06-28 fda.gov
Withdrawn EU (EMA) Onsenal 2008-11-28 europa.eu
Approved EU (EMA) Onsenal 2003-10-17 europa.eu
Approved US (FDA) CELEBREX 1998-12-31 fda.gov

Trials 398 · started per year

today
US approved 1998
EU approved 2003
2
3
10
14
27
49
30
16
18
10
13
16
8
7
7
8
15
14
14
9
12
23
13
8
10
8
6
13
8
2
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 09 trials
Phase 0 NCT06942039 Sep 2025 → Dec 2030 expected atypical teratoid rhabdoid tumor, childhood medulloblastoma, embryonal tumor with multilayered rosettes, ependymoblastoma +5 C17 Council Recruiting No outcome recorded
Phase 0 NCT04648540 Dec 2020 → Aug 2022 Cairo University Completed No outcome recorded
Phase 0 NCT03820193 Jan 2019 → Jun 2020 substance-related disorder Henry Ford Health System Completed No outcome recorded
Phase 0 NCT03599453 Jan 2019 → Sep 2020 triple-negative breast carcinoma Roswell Park Cancer Institute Completed No outcome recorded
Phase 0 NCT02362529 Feb 2015 → Apr 2019 major depressive disorder Centre for Addiction and Mental Health Completed No outcome recorded
Phase 0 NCT01901679 Jul 2013 → Aug 2014 obesity disorder Rockefeller University Completed No outcome recorded
Phase 0 NCT01796951 Feb 2013 → Feb 2016 nicotine dependence Vanderbilt University Completed No outcome recorded
Phase 0 NCT01881048 Dec 2009 → Jan 2014 female breast carcinoma University of Colorado, Denver Completed No outcome recorded
Phase 0 NCT00585156 Jun → Sep 2008 University of Utah Terminated No outcome recorded
Phase 157 trials
Phase 1 NCT07338266 Jan → Dec 2026 expected osteoarthritis, knee Avidence Therapeutics Recruiting No outcome recorded
Phase 1 NCT06076837 Jan → Dec 2025 pancreatic adenocarcinoma HonorHealth Research Institute Terminated No outcome recorded
Phase 1 NCT05281276 Sep 2022 → Mar 2024 colorectal cancer Taipei Medical University Shuang Ho Hospital Terminated No outcome recorded
Phase 1 NCT05438303 Jun → Dec 2022 AstraZeneca Completed No outcome recorded
Phase 1 NCT05512013 Feb 2022 → Apr 2023 bone resorption disease, disease of bone structure United States Army Research Institute of Environmental Medicine Completed No outcome recorded
Phase 1 NCT04120636 Mar 2021 → Jun 2024 central serous chorioretinopathy, hyalitis, macular retinal edema, occlusion of tributary of retinal vein +1 Targeted Therapy Technologies, LLC Unknown No outcome recorded
Phase 1 NCT04526197 Jul → Nov 2020 Wilson disease Alexion Pharmaceuticals, Inc. Completed No outcome recorded
Phase 1 NCT04490434 Jun → Aug 2020 Daewoong Pharmaceutical Co. LTD. Unknown No outcome recorded
Phase 1 NCT04375865 May → Jul 2020 Addpharma Inc. Completed No outcome recorded
Phase 1 NCT03878524 Apr → Dec 2020 acute myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, castration-resistant prostate carcinoma +14 OHSU Knight Cancer Institute Terminated No outcome recorded
Phase 1/225 trials
Phase 1/2 NCT03686657 Dec 2026 → Dec 2030 arthritic joint disease, hypertensive disorder, obesity disorder, type 2 diabetes mellitus ARKAY Therapeutics Withdrawn No outcome recorded
Phase 1/2 NCT07632235 Jul 2026 → Dec 2029 expected intrahepatic cholangiocarcinoma Shanghai 6th People's Hospital Recruiting No outcome recorded
Phase 1/2 NCT05756166 Feb 2024 → Apr 2025 female breast carcinoma, triple-negative breast carcinoma Roswell Park Cancer Institute Terminated No outcome recorded
Phase 1/2 NCT05476679 Sep 2022 → Jun 2023 Raziel Therapeutics Ltd. Completed No outcome recorded
Phase 1/2 NCT02770378 Nov 2016 → Oct 2018 glioblastoma University of Ulm Completed No outcome recorded
Phase 1/2 NCT02054104 Sep 2014 → Jun 2015 melanoma, respiratory system cancer, sarcoma, thoracic cancer National Cancer Institute (NCI) Terminated No outcome recorded
Phase 1/2 NCT02151448 Jul 2014 → Feb 2019 malignant pancreatic neoplasm, malignant peritoneal mesothelioma, peritoneal carcinomatosis David Bartlett Completed No outcome recorded
Phase 1/2 NCT01545141 Oct 2012 → Apr 2016 colorectal carcinoma Roswell Park Cancer Institute Terminated No outcome recorded
Phase 1/2 NCT01280006 Jan → Dec 2011 hypertensive disorder, obstructive sleep apnea syndrome, stroke disorder University of Calgary Completed No outcome recorded
Phase 1/2 NCT01021215 May 2010 → Aug 2012 nicotine dependence National Cancer Institute (NCI) Completed No outcome recorded
Phase 2150 trials
Phase 2 NCT07139405 Sep 2026 → Sep 2027 expected type 2 diabetes mellitus Myopharm Limited Not yet recruiting No outcome recorded
Phase 2 NCT07597902 Jun 2026 → Jun 2028 expected long COVID-19 Icahn School of Medicine at Mount Sinai Not yet recruiting No outcome recorded
Phase 2 NCT07494565 Mar → Dec 2026 expected diffuse large B-cell lymphoma Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 2 NCT07174570 Jan → Nov 2026 expected hepatocellular carcinoma Emory University Recruiting No outcome recorded
Phase 2 NCT07150949 Aug 2025 → Aug 2027 expected Fudan University Recruiting No outcome recorded
Phase 2 NCT07104266 Aug 2025 → Aug 2028 expected triple-negative breast carcinoma University of Sherbrooke Recruiting No outcome recorded
Phase 2 NCT07049185 Jul 2025 → Mar 2027 expected esophageal squamous cell carcinoma Peking University Cancer Hospital & Institute Not yet recruiting No outcome recorded
Phase 2 NCT06997068 Jul 2025 → Jun 2028 expected hypopharyngeal carcinoma, laryngeal carcinoma, oral cavity carcinoma, oropharyngeal carcinoma Mayo Clinic Recruiting No outcome recorded
Phase 2 NCT06903858 Jun 2025 → Apr 2028 expected colorectal cancer Sun Yat-sen University Recruiting No outcome recorded
Phase 2 NCT06505187 Feb 2025 → Sep 2026 expected University of Wisconsin, Madison Recruiting No outcome recorded
Show all 150 trials opens the full record — a long page
Phase 2/310 trials
Phase 2/3 NCT04860635 Jan 2027 → Jul 2028 Arthritis Innovation Corporation Suspended No outcome recorded
Phase 2/3 NCT05509946 Oct 2022 → Apr 2023 Indonesia University Unknown No outcome recorded
Phase 2/3 NCT03825809 Jan 2019 → Jan 2020 overdue substance-related disorder Henry Ford Health System Recruiting No outcome recorded
Phase 2/3 NCT03818932 Jan 2019 → Jan 2020 Henry Ford Health System Completed No outcome recorded
Phase 2/3 NCT00808743 May 2009 → Jul 2011 classic familial adenomatous polyposis, intestinal polyp, tumor of duodenum Radboud University Medical Center Completed No outcome recorded
Phase 2/3 NCT00934739 Jun 2007 → Dec 2012 oral cavity cancer National Health Research Institutes, Taiwan Terminated No outcome recorded
Phase 2/3 NCT00268476 Jul 2005 → Mar 2026 overdue prostate cancer Medical Research Council Active not recruiting No outcome recorded
Phase 2/3 NCT00136487 Oct 2002 → Sep 2006 prostate cancer Dana-Farber Cancer Institute Completed No outcome recorded
Phase 2/3 NCT00027976 Dec 2001 → Dec 2005 precancerous condition University of Alabama at Birmingham Withdrawn No outcome recorded
Phase 2/3 NCT00006124 Jun 2000 → Mar 2006 bladder transitional cell carcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 357 trials
Phase 3 NCT06863636 Sep 2024 → Oct 2025 overdue osteoarthritis, hip, osteoarthritis, knee Laboratorios Silanes S.A. de C.V. Recruiting No outcome recorded
Phase 3 NCT06516094 Apr 2024 → Jan 2025 chronic pain syndrome Laboratorios Silanes S.A. de C.V. Completed No outcome recorded
Phase 3 NCT06285617 Apr 2024 → Jan 2025 subacute thyroiditis Xinqiao Hospital of Chongqing Unknown No outcome recorded
Phase 3 NCT05603832 Nov 2022 → Nov 2023 Arthritis Innovation Corporation Completed No outcome recorded
Phase 3 NCT05415397 Sep 2022 → Jul 2026 overdue major depressive disorder Amsterdam UMC, location VUmc Active not recruiting No outcome recorded
Phase 3 NCT05362851 Nov 2021 → Jan 2023 osteoarthritis, knee Yooyoung Pharmaceutical Co., Ltd. Unknown No outcome recorded
Phase 3 NCT04429022 Nov 2020 → May 2022 State University of New York at Buffalo Completed No outcome recorded
Phase 3 NCT04176419 Jan 2020 → Jun 2021 Case Comprehensive Cancer Center Terminated No outcome recorded
Phase 3 NCT03974932 Jun 2019 → Dec 2020 Heron Therapeutics Completed No outcome recorded
Phase 3 NCT03586934 Jun 2018 → Jun 2019 substance-related disorder Rush University Medical Center Withdrawn No outcome recorded
Phase 461 trials
Phase 4 NCT06699966 Jun 2027 → Jun 2031 expected major depressive disorder Stony Brook University Not yet recruiting No outcome recorded
Phase 4 NCT07116564 Aug 2025 → Aug 2026 overdue Aga Khan University Recruiting No outcome recorded
Phase 4 NCT07076069 Jul 2025 → Jun 2028 expected rotator cuff syndrome Montefiore Medical Center Recruiting No outcome recorded
Phase 4 NCT06671002 Jan 2025 → Oct 2026 expected University of Michigan Recruiting No outcome recorded
Phase 4 NCT06379425 Mar 2024 → Mar 2026 overdue Northwell Health Recruiting No outcome recorded
Phase 4 NCT06159114 Dec 2023 → Jan 2025 chronic prostatitis Xintian Pharmaceutical Completed No outcome recorded
Phase 4 NCT05722002 Feb 2023 → Dec 2026 expected neuropathy, painful University of Michigan Recruiting No outcome recorded
Phase 4 NCT05288374 Feb 2022 → Nov 2023 Charles University, Czech Republic Completed No outcome recorded
Phase 4 NCT04522206 Aug 2020 → Jun 2021 vertebral column disorder NYU Langone Health Completed No outcome recorded
Phase 4 NCT04259333 Mar → Dec 2020 neuropathy, painful, substance-related disorder Blake Raggio Unknown No outcome recorded
Phase not applicable29 trials
NCT07673549 Aug 2026 → Dec 2027 expected trigeminal neuralgia Beijing Tiantan Hospital Not yet recruiting No outcome recorded
NCT07154433 Sep 2025 → May 2026 osteochondritis dissecans Second Affiliated Hospital, School of Medicine, Zhejiang University Completed No outcome recorded
NCT06722534 Feb 2025 → Jan 2029 expected Peutz-Jeghers syndrome, intestinal polyp Air Force Military Medical University, China Recruiting No outcome recorded
NCT05994287 Jan 2021 → Jan 2022 Federal State Budgetary Organization, Federal Center for Traumatology, Orthopedics and Arthroplasty Completed No outcome recorded
NCT03499743 Apr → Sep 2018 Cairo University Completed No outcome recorded
NCT03351439 Apr 2018 → Sep 2021 chronic pain syndrome Western University, Canada Completed No outcome recorded
NCT03339544 Dec 2017 → Dec 2018 pulpitis Cairo University Unknown No outcome recorded
NCT02790203 Jun 2016 → Dec 2018 ileus Sheba Medical Center Unknown No outcome recorded
NCT02413203 Mar → Nov 2015 University of Pennsylvania Completed No outcome recorded
NCT02255006 May → Oct 2014 Kyunghee University Medical Center Unknown No outcome recorded
Also used as a comparator or background therapy in 187 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 03 trials
Phase 0 NCT03590821 Background Dec 2027 → Jan 2028 expected University of Pennsylvania Not yet recruiting No outcome recorded
Phase 0 NCT06451783 Comparator May 2024 → Apr 2025 osteoarthritis, knee Xuhui Central Hospital, Shanghai Unknown No outcome recorded
Phase 0 NCT05852093 Comparator Jun 2023 → Jun 2026 overdue rotator cuff syndrome Second Affiliated Hospital, School of Medicine, Zhejiang University Not yet recruiting No outcome recorded
Phase 126 trials
Phase 1 NCT07632599 Background Jul 2026 → Jun 2027 expected ankylosing spondylitis Eighth Affiliated Hospital, Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 1 NCT07351968 Comparator Mar → Aug 2026 overdue osteoarthritis, knee Shandong Suncadia Medicine Co., Ltd. Recruiting No outcome recorded
Phase 1 NCT07171034 Comparator Sep 2025 → May 2026 overdue Hunan Kelun Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 1 NCT07559682 Comparator May → Aug 2025 overdue Sharif Medical Research Center Active not recruiting No outcome recorded
Phase 1 NCT05436678 Comparator Jul → Aug 2022 NeuroSense Therapeutics Ltd. Completed No outcome recorded
Phase 1/26 trials
Phase 1/2 NCT07246278 Comparator Nov 2025 → Nov 2026 expected Parkinson disease Tanta University Recruiting No outcome recorded
Phase 1/2 NCT04767841 Background Feb 2021 → Jun 2024 osteoarthritis, knee Sadat City University Withdrawn No outcome recorded
Phase 1/2 NCT05547659 Comparator Jan 2019 → Apr 2020 October 6 University Completed No outcome recorded
Phase 1/2 NCT02432378 Background Sep 2015 → Jun 2025 ovarian cancer Roswell Park Cancer Institute Withdrawn No outcome recorded
Phase 1/2 NCT00197912 Background Sep 2004 → Apr 2010 melanoma Herlev Hospital Completed No outcome recorded
Phase 233 trials
Phase 2 NCT07634094 Background Aug 2026 → Aug 2028 expected ovarian cancer Kalinski, Pawel, MD, PhD Not yet recruiting No outcome recorded
Phase 2 NCT07543796 Comparator Mar → Jun 2026 overdue Beijing Tide Pharmaceutical Co., Ltd Recruiting No outcome recorded
Phase 2 NCT07154316 Background Aug 2025 → Aug 2028 expected colorectal cancer Fudan University Recruiting No outcome recorded
Phase 2 NCT01344200 Comparator Jan 2024 → Jan 2026 overdue Children's Hospital of Eastern Ontario Recruiting No outcome recorded
Phase 2 NCT06185543 Comparator Nov 2023 → Sep 2025 Alzheimer disease NeuroSense Therapeutics Ltd. Terminated No outcome recorded
Phase 2/33 trials
Phase 2/3 NCT05638893 Background Feb 2021 → Mar 2022 osteoarthritis, knee Tanta University Completed No outcome recorded
Phase 2/3 NCT04562610 Comparator Nov 2020 → Oct 2024 vertebral column disorder University of California, Davis Completed No outcome recorded
Phase 2/3 NCT04342065 Comparator Jan 2019 → Jan 2020 South Egypt Cancer Institute Completed No outcome recorded
Phase 345 trials
Phase 3 NCT07414706 Background Mar 2026 → Jun 2028 expected local anesthetic poisoning Centre Hospitalier Universitaire, Amiens Not yet recruiting No outcome recorded
Phase 3 NCT06545526 Comparator Aug 2024 → Jun 2026 overdue classic familial adenomatous polyposis Yonsei University Recruiting No outcome recorded
Phase 3 NCT05965492 Background Jun 2024 → Jun 2025 spinal cord disorder University of Miami Withdrawn No outcome recorded
Phase 3 NCT06231758 Comparator Jan 2024 → Nov 2026 expected osteoarthritis, knee Mostafa Bahaa Recruiting No outcome recorded
Phase 3 NCT05644301 Comparator Sep 2023 → Sep 2026 expected major depressive disorder University of Antwerp Recruiting No outcome recorded
Phase 447 trials
Phase 4 NCT06113211 Background Oct 2024 → Sep 2026 expected disease of bone structure, substance-related disorder Henry Ford Health System Recruiting No outcome recorded
Phase 4 NCT06245109 Comparator Feb 2024 → Mar 2028 expected osteoarthritis, knee Northwestern University Recruiting No outcome recorded
Phase 4 NCT05974501 Background Sep 2023 → Jan 2024 osteoarthritis, knee University of Miami Completed No outcome recorded
Phase 4 NCT05488847 Background Jun 2022 → Dec 2024 overdue arthropathy Henry Ford Health System Active not recruiting No outcome recorded
Phase 4 NCT06336993 Comparator Jan 2022 → Jun 2023 Zhejiang Provincial Tongde Hospital Completed No outcome recorded
Phase not applicable24 trials
NCT07353372 Background Jan 2026 → Sep 2028 expected Xuanwu Hospital, Beijing Not yet recruiting No outcome recorded
NCT07032883 Background Jun 2025 → Feb 2026 overdue female breast carcinoma Cairo University Not yet recruiting No outcome recorded
NCT06344403 Background Jun 2025 → Oct 2026 expected herpes zoster Beijing Tiantan Hospital Active not recruiting No outcome recorded
NCT06602167 Background Oct 2024 → Jul 2027 expected breast cancer, digestive system cancer, hand-foot syndrome Affiliated Hospital of Qinghai University Recruiting No outcome recorded
NCT06328153 Comparator Mar 2024 → Jan 2026 osteoarthritis, knee Guangdong Provincial Hospital of Traditional Chinese Medicine Unknown No outcome recorded

Press releases naming this drug 5 releases

DateIssuerRelease
2016-11-13 Pfizer Landmark Study Demonstrates Pfizer’s Celebrex (Celecoxib)Has Similar Cardiovascular Risk As Compared To Prescription Doses Of Ibuprofen and Naproxen pfizer.com
2014-12-10 Teva Branded Pharmaceutical Products R&D, Inc. Teva Announces Launch of First Generic Celebrex® Capsules in the United States tevapharm.com
2014-05-30 Teva Branded Pharmaceutical Products R&D, Inc. Teva Receives Favorable Court Decision Regarding Generic Celebrex® Capsules; Teva Should Receive Sole Exclusivity for Generic Celebrex® Capsules tevapharm.com
2014-04-17 Teva Branded Pharmaceutical Products R&D, Inc. Teva Settles Patent Litigation with Pfizer on Celebrex® tevapharm.com
2007-03-21 Teva Branded Pharmaceutical Products R&D, Inc. Teva Provides Update On Generic CELEBREX® Litigation tevapharm.com

Evidence & citations 28 cited values

Every value below carries the sentence it was read from. 590 sources stand behind the page.

FieldValueCited text
Known as CELECOXIB “The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating...” NCT02641314
552

“Participants with v-akt murine thymoma viral oncogene homologue 1 (AKT1) gene mutations will receive a drug called Celecoxib, which inhibits a protein called v-akt murine...” NCT02208583

“Purpose: pharmacokinetic interactions and safety of AD-2111 and AD-2112 in healthy adult volunteers Condition or disease : Pain Intervention/treatment Drug : AD-2111(Celecoxib...” NCT04375865

“Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase...” PMID 25403311 Nov 2014

“A Six Week Double-Blind, Randomized, Multicenter Comparison Study of the Analgesic Effectiveness of Celecoxib 200 mg BID Compared to Tramadol Hydrochloride 50 mg QID in...” NCT00290901

“Subjects in the oral administration group will receive the following pre-emptive analgesic drugs, acetaminophen 1,000mg, Celecoxib 200mg and gabapentin 600mg via the oral route...” NCT04562610

“PrimeC is a fixed-dose oral combination of celecoxib and ciprofloxacin designed to target ALS-related mechanisms, including neuroinflammation, iron homeostasis, and...” PMID 41837970 May 2026

“Nonsteroidal anti-inflammatory drug celecoxib (200 mg on request, up to two times daily)27 and tramadol (100 mg on request, up to 400mg daily) will be available for as-needed analgesia.” NCT06344403

“PK101, a fixed-dose combination (FDC) comprising PG201, a 12-herb extract used in OA treatment in traditional East Asian medicine, and celecoxib, a selective cyclooxygenase-2 inhibitor” PMID 39560548 Nov 2024

“Immediately after surgery, patients will receive oral acetaminophen 500 mg plus celecoxib 400 mg. Thereafter, celecoxib 200 mg BID and acetaminophen 500 mg Q6H will be administered.” NCT07154433

“Drug: Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd), which will be applied 1 time daily( taken 0.2g one time orally ) Time of treatment :4 weeks Other Name: celecoxibNCT03563690

Celecoxib 6mg/kg (maximum 400mg) by mouth once then 3 mg/kg (maximum 200mg) every 12 hours around the clock for 2 days, then as needed for pain thereafter (40 doses)” NCT06671002

“A Phase I Trial of Postoperative Radiation With Dose-Escalation of A Cox-2 Inhibitor, Celebrex™ (CELECOXIB) in Patients With Soft Tissue Sarcoma of the Extremity” NCT00450736

“Disitamab Vedotin (2mg/kg, q2w), Tislelizumab (2mg/kg, q2w) combined with low-dose capecitabine 0.5g bid chemotherapy and the COX2 inhibitor celecoxib 200mg bid” NCT05578287

“Effectiveness and Safety of Celecoxib (Celebrex 200 mg) Combined With Joins in the Treatment of Degenerative Knee Osteoarthritis: a Randomized Controlled Trial” NCT04718649

“Participants in tramadol/APAP group will receive celecoxib 200 milligram (mg) and fixed dose combination of tramadol (37.5 mg)/APAP (325 mg) as add on therapy” NCT01728246

“500 mg metformin-HCL XR plus 100 mg celecoxib once-a-day in the morning and 160 mg valsartan 6 hours later once-a-day in the afternoon for 26 weeks.” NCT03686657

“The second group was treated for 10 days with NSAIDs (naproxen 500 mg/d or celecoxib 200 mg/d) according to the indications and contraindications.” NCT01374269

“The purpose of the study is to find out whether the drug celecoxib has beneficial effects on people with pre-cancerous lesions of the pancreas.” NCT00198081

“Drug (Celecoxib as 200mg twice daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery” NCT02748707

“2 tablets of PrimeC administered twice daily (4 tablets a day), total daily dose of 1360 mg ciprofloxacin and 136 mg celecoxib orally.” NCT06185543

“DFN-15, a novel oral liquid formulation of celecoxib, is being developed for the acute treatment of migraine with or without aura.” PMID 28748412 Oct 2017

“Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients \> 50 kg)” NCT01858571

Celecoxib: 200 mg, Oral, two times per day for five days with a visually matching sequential placebo in between of two doses.” NCT01280006

“Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.” NCT01837433

“The efficacy and safety of the association of celecoxib \[a selective cyclooxygenase-2 (COX-2) inhibitor\] and pregabalin” NCT03584074

“The study drugs are a combination of celecoxib (Celebrex®), Interferon-α2b (IFN), and rintatolimod (Ampligen®), or CKM.” NCT02615574

“N-acetylcysteine and celecoxib start day of admission (prior to conditioning regimen) and continue through day +100” NCT02171104

“All patients received oral paracetamol 500mg, 4 times a day and oral celecoxib 200mg, 2 times a day after surgery.” NCT04314505

“Patients will be randomized to receive celecoxib suspension 6 mg/kg one hour prior to their scheduled surgery.” NCT00849966

“IMP would have been either placebo, tanezumab, celecoxib, naproxen or diclofenac administered in parent study.” NCT02674386

“IMP would have been either placebo, tanezumab, celecoxib, naproxen, diclofenac, administered in parent study” NCT03031938

“Orally administered NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks” NCT02528188

“Celebrex(celecoxib, pfizer) 200mg twice daily is administered for 5 days before FMD measurement.” NCT02255006

“Effect of Celecoxib and Etoricoxib on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol” NCT01304069

“* Celecoxib 400 mg by mouth once then 200 mg every twelve hours as needed for pain (10 doses)” NCT05722002

“Acetaminophen 975 mg Celecoxib 200 mg Gabapentin 300 mg Oxycodone 10 mg Extended Release” NCT04522206

“starts thalidomide (50) 4# per day and celecoxib (Celebrex)(200) 2# bid for three weeks” NCT00934739

celecoxib (CEL) (200 mg) given once daily versus placebo in knee osteoarthritis (OA).” PMID 26313454 Aug 2015

Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment” NCT00101686

“1000mg oral acetaminophen + 400mg oral celecoxib given within one hour of incision” NCT02643394

“Postoperative analgesia regimen: Paracetamol 1 g ×4/day; Celecoxib 100 mg ×2/day” NCT07414706

“Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks” NCT00809354

“One dose of Pregabalin 100mg and Celecoxib 400mg along with interscalene block” NCT07076069

“then followed by oral celecoxib 200 mg once or twice daily till pain subsides.” NCT07032883

“receive additional celecoxib 200mg bid every days during chemotherapy period.” NCT03498326

“standard background therapy consisting of celecoxib 0.2g orally once daily” NCT07632599

“including oral celecoxib, topical diclofenac, and other skin protectants” NCT06602167

“placebo tablets BID plus celecoxib 200 mg orally once daily for 12 weeks” PMID 38869746 Jun 2024

Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery” NCT01545141

“single 4.8 mL dose of 120-mg celecoxib oral solution or placebo” PMID 34447267 Aug 2021

“200 mg celecoxib (Celebra®, Pfizer) is given p.o. every day” NCT00197912

“NSAIDs: ibuprofen, celecoxib, or diclofenac/misoprostol” NCT01943435

“Metformin 1000mg tablet plus celecoxib 200 mg capsule” NCT04767841

“combination of Toripalimab,regorafenib and celecoxibNCT05933980

“standard oral NSAIDs (e.g., ibuprofen or celecoxib)” NCT07353372

“625 mg intra-articular sustained-release celecoxibNCT05603832

“Single dose 150 mg celecoxib as formulation D1” NCT00925106

“YYC301-1: Tramadol 37.5Mg+ Celecoxib 200mg” NCT05362851

“A long-acting formulation of celecoxibNCT07338266

Celecoxib Dosage: 200 mg per tablet” NCT06420388

Celecoxib 200g 1 hour before surgery” NCT07116564

“COX-2 inhibitor (Celecoxib)” NCT03391570

Celecoxib 200 mg/24 hours” NCT04648540

celecoxib 100 mg BID” NCT03062644

“200 mg celecoxib qd” NCT00665431

“10. COX2: CelecoxibNCT02101385

Celecoxib 400mg” NCT03549611

celecoxibNCT00849966

CelecoxibNCT01638962

CelecoxibNCT03885596

NCT01796951

NCT00038103

NCT00215345

NCT02839694

NCT00037817

NCT05324163

NCT02355236

NCT02840162

NCT00084370

NCT02198924

NCT00020878

NCT00357617

NCT00141193

NCT00141154

NCT02725411

NCT04342065

NCT00663767

NCT00141102

NCT00533247

NCT00108186

NCT02429427

NCT02726659

NCT00084578

NCT06076837

NCT03912428

NCT00068770

NCT00471341

NCT00194090

NCT00084721

NCT00357500

NCT03108482

NCT00424294

NCT02987920

NCT00043680

NCT00603759

NCT00643799

NCT00056082

NCT00981201

NCT00037180

NCT00068653

NCT01860833

NCT03699293

NCT02502006

NCT03694873

NCT00807846

NCT02179645

NCT00085163

NCT00030407

NCT05994287

NCT00813241

NCT00174317

NCT02030964

NCT05324995

NCT00780325

NCT02502500

NCT02084511

NCT05438303

NCT00640627

NCT05644301

NCT00030420

NCT00994461

NCT00201773

NCT02343614

NCT06316843

NCT00006381

NCT01729923

NCT01425853

NCT01313429

NCT02108366

NCT00314262

NCT00043043

NCT01968070

NCT02307305

NCT00084448

NCT01695226

NCT00596219

NCT00068432

NCT02151448

NCT00022399

NCT01705106

NCT06159114

NCT06545526

NCT00953849

NCT02845336

NCT07104266

NCT00290680

NCT00585312

NCT00762463

NCT01543685

NCT01479829

NCT02537925

NCT03570554

NCT00291694

NCT06328153

NCT01067989

NCT00565500

NCT03473665

NCT00585156

NCT01425476

NCT00139776

NCT06379425

NCT04860635

NCT02260336

NCT00846430

NCT00640809

NCT00153660

NCT00104767

NCT00153673

NCT07559682

NCT00175032

NCT03067194

NCT00698204

NCT00729495

NCT01503385

NCT01124435

NCT00328432

NCT03926338

NCT05512013

NCT03625050

NCT00546507

NCT00152828

NCT01756989

NCT04469530

NCT05911126

NCT01143545

NCT00662558

NCT00036283

NCT01555073

NCT00665457

NCT03896113

NCT02389465

NCT00023621

NCT02736019

NCT02736071

NCT00081848

NCT00023660

NCT02885974

NCT00292721

NCT01323595

NCT01678313

NCT06997068

NCT00081224

NCT07673549

NCT05509946

NCT00057980

NCT00293436

NCT03026140

NCT00549549

NCT01462435

NCT01623921

NCT06903858

NCT02160301

NCT00355576

NCT02934191

NCT02711579

NCT00055978

NCT06009900

NCT02850211

NCT05077332

NCT02362529

NCT02413203

NCT00295035

NCT07351968

NCT05547659

NCT00070057

NCT00336960

NCT00005094

NCT00001693

NCT01020279

NCT02739035

NCT00137852

NCT02739204

NCT00058006

NCT05281276

NCT00081263

NCT02054104

NCT00808743

NCT00624559

NCT00551005

NCT02827487

NCT05436678

NCT06699966

NCT00359151

NCT01285817

NCT02131012

NCT00700687

NCT03599453

NCT06451783

NCT01186887

NCT04673578

NCT00218205

NCT07494565

NCT00630929

NCT00112502

NCT00640432

NCT00499655

NCT00088959

NCT00473980

NCT03728179

NCT02638896

NCT04041050

NCT07139405

NCT03185871

NCT00296127

NCT00066716

NCT00137033

NCT02961998

NCT05077969

NCT00525096

NCT00050479

NCT02790203

NCT03850587

NCT00176813

NCT00045591

NCT00500279

NCT05415397

NCT00165451

NCT00070486

NCT03305068

NCT05256823

NCT04786548

NCT00136487

NCT00177853

NCT00450736

NCT06516094

NCT07049185

NCT02192190

NCT00065169

NCT07597902

NCT05232461

NCT04081389

NCT02876094

NCT03818919

NCT03464552

NCT06285617

NCT06231758

NCT04120636

NCT05327751

NCT03818932

NCT00256321

NCT02037165

NCT03059238

NCT00025051

NCT03645187

NCT00007189

NCT00778193

NCT01554163

NCT06505187

NCT06245109

NCT00080782

NCT01631669

NCT03523832

NCT04082715

NCT03084536

NCT00484718

NCT07154316

NCT02079727

NCT00442676

NCT00268476

NCT02993029

NCT02779166

NCT00163241

NCT01356290

NCT01762891

NCT05765747

NCT07174570

NCT07543796

NCT02071303

NCT03820193

NCT01449630

NCT01017380

NCT01800799

NCT00087256

NCT00597415

NCT04505657

NCT00223691

NCT00652925

NCT02401295

NCT03949673

NCT05731726

NCT04490434

NCT05488847

NCT01838044

NCT03878524

NCT00373685

NCT05555823

NCT00006124

NCT05476679

NCT02703363

NCT03822520

NCT05756166

NCT00633438

NCT00072072

NCT00092352

NCT01111591

NCT02703259

NCT00092365

NCT04176419

NCT00061893

NCT02408146

NCT05062083

NCT01632566

NCT01632579

NCT00088972

NCT00300729

NCT03540030

NCT00061906

NCT00046839

NCT00687388

NCT00032890

NCT06722534

NCT01041781

NCT00589186

NCT01709656

NCT00583453

NCT00633386

NCT00648141

NCT00062101

NCT02090933

NCT00520091

NCT03499743

NCT04147013

NCT01765296

NCT00716547

NCT01549743

NCT00638807

NCT00014404

NCT00027976

NCT00052611

NCT00092768

NCT01158534

NCT05237297

NCT00092781

NCT05852093

NCT00033371

NCT00258232

NCT00538031

NCT04115098

NCT02301234

NCT02351934

NCT02688400

NCT06336993

NCT03643744

NCT00101335

NCT00150280

NCT00274898

NCT00181532

NCT00001955

NCT00072540

NCT01062113

NCT00062179

NCT00072553

NCT02979197

NCT00581685

NCT00402987

NCT01150045

NCT06942039

NCT00135018

NCT01881048

NCT02484664

NCT00527982

NCT00931203

NCT04090684

NCT00101062

NCT03825809

NCT05288374

NCT00047281

NCT01768520

NCT04488081

NCT00047294

NCT00546832

NCT05962957

NCT02758782

NCT00520338

NCT02759198

NCT04259333

NCT03337607

NCT01344213

NCT03710876

NCT00598234

NCT04165850

NCT00653250

NCT00005878

NCT04093323

NCT00894790

NCT01344200

NCT03586934

NCT00009230

NCT00686140

NCT00346216

NCT05637086

NCT03404479

NCT02432378

NCT00503035

NCT00985439

NCT02280694

NCT00261586

NCT02574728

NCT00064181

NCT01021215

NCT07634094

NCT01354145

NCT01175772

NCT04790812

NCT00970502

NCT00964431

NCT00093678

NCT04162873

NCT00346801

NCT06863636

NCT00976716

NCT00304317

NCT03331315

NCT00400374

NCT00231829

NCT02695745

NCT00581971

NCT00188565

NCT07632235

NCT00608595

NCT00639483

NCT00230399

NCT00446797

NCT00904605

NCT01341405

NCT00685568

NCT04639804

NCT03190603

NCT00582660

NCT01341496

NCT00212108

NCT00904397

NCT02172040

NCT04765644

NCT05085574

NCT00551889

NCT00075673

NCT02667730

NCT04020588

NCT00520845

NCT01220973

NCT02602509

NCT03403634

NCT00882388

NCT00348452

NCT01872910

NCT04814355

NCT01769625

NCT00305643

NCT01668680

NCT00073866

NCT04374981

NCT06004947

NCT01284504

NCT02099136

NCT03864575

NCT00159484

NCT03121963

NCT00099047

NCT00466505

NCT05434065

NCT02528201

NCT00065559

NCT02770378

NCT00447759

NCT00073970

NCT07150949

NCT00504660

NCT01849055

NCT03974932

NCT04015908

NCT00365313

NCT07246278

NCT00526214

NCT02600247

NCT03590821

NCT00211952

NCT00571701

NCT04526197

NCT00183807

NCT00620867

NCT04429022

Known as AD-2111 “Purpose: pharmacokinetic interactions and safety of AD-2111 and AD-2112 in healthy adult volunteers Condition or disease : Pain Intervention/treatment Drug : AD-2111(Celecoxib...” NCT04375865
Known as CBX “using celecoxib (CBX), a cyclooxygenase 2 (COX-2) inhibitor” PMID 31630035 Oct 2019
Known as CEL celecoxib (CEL) (200 mg) given once daily versus placebo in knee osteoarthritis (OA).” PMID 26313454 Aug 2015
Known as CELBESTA ClinicalTrials.gov intervention name — accepted as the source's own label NCT02780323
Known as Celeberex “Celecoxib is a nonsteroidal anit-inflammatory drug (NSAID) marketed worldwide (in the United States \[US\] as Celeberex) and approved for the relief of signs and symptoms of...” NCT00424294
Known as Celebra ClinicalTrials.gov intervention name — accepted as the source's own label NCT03068260
Known as celebra (celecoxib) celebra (celecoxib)NCT01756989
Known as Celebrex “This study will investigate the benefits of administering celecoxib (Celebrex), a selective cyclooxygenase -2 (COX-2) inhibitor, in treating osteoarthritis (OA) subjects...” NCT00359151
67

“This 2-part study will evaluate the effectiveness and side effects of two anti-inflammatory drugs for relieving pain and improving jaw function in patients with...” NCT00001955

“The selective cyclo-oxygenase 2 (COX-2) inhibitor, celecoxib (Celebrex, Pfizer Inc.), is being investigated as an anticancer agent in chemoprevention and adjuvant therapeutic...” NCT00596219

“Group I who will receive Tramadol 100mg (Trama SR®, Global Napi) orally 1 hour before the procedure, group II who will receive Celecoxib 200mg (Celebrex® 200, Pfizer) 1 hour...” NCT02071303

“The patients whose endometrial biopsy shows grade 2 or 3 endometrioid-type, clear cell, and papillary serous types of uterine cancers will be put on a selective COX-II...” NCT00231829

“A Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of Once Daily Celebrex® (Celecoxib) vs. Placebo in the Treatment of Subjects With Osteoarthritis of...” NCT00640627

“A Double-Blind, Placebo-Controlled, Randomized Comparison Study of the Efficacy of Celebrex 400 mg Single Dose Pre and Celebrex 200 mg Post Ambulatory Arthroscopic Knee Surgery...” NCT00633438

“In addition, we aim to determine the effect of celecoxib (Celebrex) on tumour oxygenation, interstitial fluid pressure, COX-2 levels, prostaglandin E2 levels, angiogenesis and...” NCT00152828

“To determine if Celebrex (Celecoxib) is as effective as Toradol (Ketorolac) at controlling postoperative pain when given in addition to standard postoperative pain control regimens.” NCT03331315

“A Double-Blind, Placebo-Controlled, Randomized 24-Month Study, Assessing The Effect Of Celecoxib (Celebrex) Long Term Treatment On Hip Osteoarthritis (OA) Progression OSCARE” NCT00163241

“A Phase II Trial Of Celecoxib (Celebrex) And Capecitabine (Xeloda) Combined With Pelvic Irradiation As Neoadjuvant Treatment Of Stage II or III Adenocarcinoma Of The Rectum” NCT00081224

“A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.” PMID 17084549 Nov 2006

“A Phase I Trial of Postoperative Radiation With Dose-Escalation of A Cox-2 Inhibitor, Celebrex™ (CELECOXIB) in Patients With Soft Tissue Sarcoma of the Extremity” NCT00450736

“Effectiveness and Safety of Celecoxib (Celebrex 200 mg) Combined With Joins in the Treatment of Degenerative Knee Osteoarthritis: a Randomized Controlled Trial” NCT04718649

“BAT1306 100mg /pembrolizumab 200mg on day 1 + aspirin 200mg oral (celebrex 400mg oral when there is contraindication to aspirin) on day 1-21 every three weeks” NCT03638297

Celebrex (Celecoxib) is a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat arthritis, pain, menstrual cramps, and colonic polyps.” NCT00598234

“Drug generic names: celecoxib (celebrex), naproxen/esomeprazole (vimovo), acetaminophen/tramadol (ultracet ER), oxycodone/naloxone (targin)” NCT02307305

“Celecoxib (Celebrex®) is a drug that lessens the action of an enzyme called cyclooxygenase-2 (COX-2) also known as a "COX-2 inhibitor".” NCT00188565

“Once Daily Celebrex (Celecoxib) and Naproxen 500 mg Twice Daily in the 6-month Treatment of Subjects With Osteoarthritis of the Knee” NCT00643799

Celebrex (also called Celecoxib) is an oral medication that is approved by the FDA for pain in the treatment of arthritis.” NCT00183807

“Drug generic names: celecoxib (celebrex), Pregabalin (Lyrica), acetaminophen/tramadol (ultracet ER), oxycodone (Ircodon)” NCT02600247

“The study drugs are a combination of celecoxib (Celebrex®), Interferon-α2b (IFN), and rintatolimod (Ampligen®), or CKM.” NCT02615574

“Patients were treated with sorafenib taking capsules celecoxib (Celebrex) at the same time, 200mg/day, last 6 months” NCT02961998

“A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects” NCT00807846

“non-steroid anti-inflammatory drugs (NSAID):"celecoxib", "Celebrex®" 0.2g Bid(twice a day),PO (Per Os)” NCT01709656

Celebrex(celecoxib, pfizer) 200mg twice daily is administered for 5 days before FMD measurement.” NCT02255006

“starts thalidomide (50) 4# per day and celecoxib (Celebrex)(200) 2# bid for three weeks” NCT00934739

“Celecoxib (Celebrex®, G.D. Searle \& Co., Chicago, IL), one 200 mg oral capsule QD” NCT00904605

“Once Daily Celebrex (Celecoxib) and Three Times Daily Ibuprofen vs. Placebo” NCT00630929

“Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer” NCT00136487

“commercial formulation of celecoxib 400-mg oral capsules (Celebrex®)” PMID 28748412 Oct 2017

“celecoxib (Celebrex) 400 mg one hour prior to surgery or placebo” NCT03305068

“Celecoxib (Celebrex) is an FDA approved drug to treat arthritis.” NCT00215345

Celebrex 400mg PO, Lyrica 75mg x1 dose pre-op, Tramadol 50mg x 1” NCT06113211

Celebrex cap. (celecoxib 200mg) : once daily, for 12 weeks” NCT01768520

Celebrex: po, 200mg, qd, six weeks” NCT00602901

“Celecoxib (Celebrex)” NCT07104266

“Celecoxib (Celebrex)” NCT00007189

“Celecoxib (Celebrex)” NCT00846430

“Drug: CelebrexNCT02456363

CelebrexNCT02602509

NCT07171034

NCT03563690

NCT01901679

NCT00592319

NCT00664690

NCT00006299

NCT01258868

NCT03472469

NCT01535417

NCT03184493

NCT03351439

NCT01576419

NCT02110719

NCT00137410

NCT00486460

NCT05930080

NCT02115074

NCT00177866

NCT00614406

NCT05974501

NCT01934933

NCT04788654

NCT03339544

NCT01129245

NCT03859024

NCT05965492

NCT03282838

Known as Celebrex (Registered Trademark) “This study will determine whether the drug celecoxib (Celebrex® (Registered Trademark)) can help stabilize or improve vision in patients with age-related macular degeneration...” NCT00043680
Known as Celebrex200 “will receive oral Celecoxib 200 mg capsule (Celebrex®200, Pfizer, USA) once 3 hours before the colposcopic guided biopsy” NCT03464552
6

“Celecoxib 200 mg (Celebrex® 200, Pfizer,USA) administered orally immediately, 12 h and 24 h after randomization.” NCT03694873

“Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to hyoscine butyl bromide” NCT03499743

“Women will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) orally 2 hours before IUD insertion.” NCT02827487

“Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to Tramadol” NCT02736019

“Celecoxib 200 mg (Celebrex® 200, Pfizer,USA) administered orally 2 h before the procedure” NCT04505657

“one capsule of Celecoxib 200 mg (Celebrex 200, Pfizer, USA) simultaneously.” NCT05911126

Known as celecoxib (Celebrex) “celecoxib (Celebrex®)” NCT02615574
4

celecoxib (Celebrex)NCT01769625

celecoxib (Celebrex)NCT01425476

“Celecoxib: Celebrex” NCT01344213

“celecoxib(celebrex)” NCT00526214

Known as Celecoxib, ATC M01AH01 Celecoxib, ATC M01AH01NCT05415397
Known as Celecoxib, Celebra, Pfizer “Celecoxib, Celebra®, Pfizer” NCT00197912
Known as CTC “BACKGROUND: STARDOM2 is a randomized, double-blind, phase 3 trial evaluating the efficacy and safety of co-crystal of tramadol-celecoxib (CTC)-a first-in-class analgesic...” PMID 35974668 Sep 2022
Known as CXB “We conducted a randomised trial of celecoxib (CXB) versus CXB+diflouromethylornithine (DFMO) to determine the synergistic effect, if any.” PMID 25792707 Mar 2015
Known as Drug: Celebrex Drug: CelebrexNCT02456363
Known as ELYXYB “Celecoxib Oral Solution (ELYXYB)” PMID 34447267 Aug 2021
Known as Episcleral Celecoxib “Drug: Episcleral CelecoxibNCT04120636
Known as F14 “This is a Phase 3, randomized, double blind, multicenter study to evaluate the analgesic efficacy and safety of a single intra-articular dose of F14 (625 mg sustained release...” NCT05603832
1

“Drug: F14 (sustained release celecoxib)” NCT04860635

Known as HD042 “the HD042 (Celecoxib) at 20uM concentration can inhibit HBV DNA, HBsAg and HBeAg by 70.87%, 88.52% and 87.55% respectively, without significant cytotoxicity.” NCT05256823
Known as MR308 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02982161
1

NCT03062644

Known as SC-58635 “Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps” NCT00141193
3

“Clinical Protocol For A Phase II Double-Blind, Placebo-Controlled, Randomized Study Of Celecoxib (Sc-58635) In Oral Premalignant Lesions, Investigator IND” NCT00036283

“Clinical Protocol for an Open Label Study of Celecoxib (SC-58635) on the Acute Effect of Human UV-Irradiation” NCT02090933

“Celecoxib (SC-58635)” NCT00001693

Known as YM177 “celecoxib (YM177) 200 mg bid” NCT00141154
2

“Celecoxib (YM177)” NCT00976716

NCT01118572

Action Inhibit “Celecoxib, is in oral anti-inflammatory and analgesic agent that acts by selectively inhibiting cyclooxygenase 2 (COX-2)” NCT00001955